Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEPPER: Strategies for Stopping Chronic PPI Therapy
NCT05629143Phase 4Active, not recruiting
- Sponsor
- UZ Leuven
- Start
- May 2023
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in gastroesophageal reflux disease (GERD) and dyspepsia (3 arms), sponsored by UZ Leuven. Primary endpoint: Success of de-prescription strategy at 15 months. Started May 2023; status: active, not recruiting.
02
Conditions
gastroesophageal reflux disease (GERD)dyspepsia
Beyond the preview
Go deeper on NCT05629143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629143.